Compare AbCellera Biologics Inc (ABCL) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs KKR & Co Inc — how do they compare? AbCellera Biologics Inc trades at $10.03 (market cap $2.99B), while KKR & Co Inc trades at $110.52 (market cap $99.61B). The key difference: KKR & Co Inc is far larger — about 33.3× AbCellera Biologics Inc's market cap, and KKR & Co Inc pays a 0.7% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | KKR | |
|---|---|---|
Market Cap | $2.99B | $99.61B |
Sector | Health | Financials |
52-Week High | $9.76 | $149.34 |
52-Week Low | $2.78 | $83.88 |
Enterprise Value | $2.58B | $22.17B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
KKR's stock trades at $110.37, up 6.3% today, showing strong momentum near recent highs. The technical outlook is bullish with the price above key moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $1.63, beating estimates of $1.43, with revenue growth supported by recent acquisitions including Integer Holdings and Medicover India. Analyst sentiment remains overwhelmingly positive with 24 buy ratings and a $127.22 consensus price target.
KKR presents a compelling investment case with strong earnings momentum, strategic acquisitions expanding its healthcare and infrastructure portfolios, and robust analyst support. However, risks include execution challenges from recent M&A activity, potential market volatility affecting asset valuations, and the stock's current premium valuation multiples. The company's ability to integrate acquisitions and maintain fundraising momentum will be key drivers of future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
